ARVN
ARVINAS, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.26
+4.16%Oct 7, 2026, 11:03 UTC
ARVINAS, INC. reported new oculomotor-function and biomarker data from the Phase 1 clinical trial of its Parkinson’s disease drug ARV-102.
Oct 1, 2026, 20:01 UTC
Arvinas announced that novel biomarker data from a Phase 1 clinical trial of ARV-102, a PROTAC LRRK2 degrader, in Parkinson's disease participants will be presented at the 2026 International Congress of Parkinson's Disease and Movement Disorders in Seoul, Korea, October 4-8, 2026.
Source:Sep 29, 2026, 20:01 UTC
Arvinas granted a newly hired employee an option to purchase 64,766 shares of common stock and 42,388 restricted stock units as of September 28, 2026, under Nasdaq Listing Rule 5635(c)(4).
Source:Sep 28, 2026, 11:00 UTC
Arvinas announced that the first patient has been dosed in a Phase 1/2 clinical trial of ARV-6723, its first immuno-oncology candidate, in advanced solid tumors.
Source:Sep 1, 2026, 20:01 UTC
Arvinas, Inc. granted 45,696 restricted stock units to a newly hired employee on August 31, 2026, as an inducement award under Nasdaq Listing Rule 5635(c)(4).
Source:Aug 4, 2026, 14:06 UTC
Arvinas entered into an out-licensing agreement for VEPPANU with Rigel Pharmaceuticals in the first half of 2026.
Source:Aug 4, 2026, 13:51 UTC
Arvinas, Inc. reported Q2 2026 earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share, and compared to a loss of $0.84 per share in the same quarter last year.
Source:Aug 4, 2026, 11:00 UTC
Arvinas secured the first-ever regulatory approval of its PROTAC drug VEPPANU.
Jun 17, 2026, 00:00 UTC
Rigel Pharmaceuticals completed the acquisition of exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant) from Arvinas entities and Pfizer.